Pharmacodynamic characteristics of velkeid efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins

Abstract

Aim. To ascertain individual sensitivity to veikeid in patients with resistant and recurrent multiple myeloma (MM) by determination of free light chains (FLC) of serum immunoglobulins.
Material and methods. Forteen patients with MM stage III (Gcappa-5, Glambda-2, Acappa-3, Alambda-1, BJcappa-3) aged 52-75 years with documented resistance to treatment or recurrence received second-line monotherapy with velkeid. The drug was injected intravenously (jet) in a dose 1.3 mg/m2 on the treatment day 1, 4, 8 and 11. Free light chains concentration was examined with antibodies to their latent determinants (Binding Site, UK) on nephelometer (Hitathi-911, Japan) on velkeid treatment day 1, 2, 3, 5, 9 and 12.
Results. Nine patients showed lowering of FLC concentration and responded to treatment by Durie criteria.
Conclusion. Dynamic follow-up of FLC concentration of the tumor clone in resistant and recurrent MM evaluates pharmacodynamics of the drug. The method provides prognosis of late clinical results.

References

  1. Bradwell A. R. Serum free light chain analysis. 4-th ed. Birmingem: The Binding Site Ltd., UK; 2006.
  2. Pratt G., Graham P. M., Keith R. et al. The tumor kinetics of multiple myeloma following autologeus stem cell transplantation as assessed by measuring serum free light chains. Leukemia and Lymphoma 2006; 47(1): 21-28.
  3. Katzmann Y. A., Dispenzieri A., Kyle R. et al. Elimination of the need for urine studies of monoclonal gammapathies by the combined use of strum immunofixation and serum free light chain assays. Blood 2006; 108 (11): 341-345.
  4. Kumar S., Rajkumar S. V., Plevak M. et al. Comparison of serum free light chain levels and 24 hour urinary monoclonal protein secretion in patients with myeloma: concordant changes with response to therapy. Blood 2006; 108 (11): 355b.
  5. Kertsonis M. C., Vassilakopoulis T. P., Kafasi N. et al. Serum free light chain ratio (FLCR) at diagnosis constitute a powerful prognostic factor of survival in multiple myeloma (MM). Blood 2006; 108 (11): 1004a.
  6. Голенков А. К., Митина Т. А., Луцкая Т. Д. и др. Клиническое значение анализа свободных легких цепей иммуноглобулинов сыворотки при множественной миеломе с различным ответом на химиотерапию. Рос. биотер. журн. 2007; 3 (6): 71-75.
  7. Min C.-Ki, Eom Ki-Seong, Lee S. et al. Changes in serum free light chain and biochemical markers in patients with multiple myeloma rectiving bortezomib treatment. Blood 2006; 108 (11): 1-7.
  8. Durie B. G. M. The importance of the new international uniform response criteria for multiple myeloma. Am. J. Hematol. Oncol. 2007; 6 (5): 15-18.

Statistics

Views

Abstract: 96

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Golenkov A.K., Mitina T.A., Kogarko I.N., Lyubimova N.V., Klinushkina E.F., Baryshnikov A.Y., Golenkov A.K., Mitina T.A., Kogarko I.N., Lyubimova N.V., Klikushkina E.F., Baryshnikov A.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies